Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Solid Tumors
Latest Information Update: 11 Apr 2025
At a glance
- Drugs SV 101 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 06 Apr 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 06 Apr 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Jul 2025.
- 02 May 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.